Investigational drugs, biological products, and devices; expanded access. (HB2050)

Introduced By

Del. Mark Sickles (D-Alexandria) with support from 6 copatrons, whose average partisan position is:

Those copatrons are Del. Mark Cole (R-Fredericksburg), Del. Patrick Hope (D-Arlington), Del. Kaye Kory (D-Falls Church), Del. Delores McQuinn (D-Richmond), Del. Marcus Simon (D-Falls Church), Sen. Lionell Spruill (D-Chesapeake)


Passed Committee
Passed House
Passed Senate
Signed by Governor
Became Law


Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such drug, product, or device available to a person who has a terminal illness when (i) the person has a terminal condition; (ii) the person has, in consultation with his physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration; (iii) the person's physician has recommended treatment with an investigational drug, biological product, or device; and (iv) the person has provided written informed consent. The bill provides that a manufacturer that provides such drug, product, or device may provide it free of charge or may require the person to pay costs associated with its manufacture. Read the Bill »


Bill Has Failed


01/14/2015Prefiled and ordered printed; offered 01/14/15 15101266D
01/14/2015Referred to Committee on Health, Welfare and Institutions
01/20/2015Assigned HWI sub: Subcommittee #1
01/28/2015Impact statement from VDH (HB2050)
02/11/2015Left in Health, Welfare and Institutions